Gastritis, Gastric Cancers, and Submucosal Tumors

• Audio chapter
  Single-voice audio, listen on the commute.
• ABIM-format MCQs
  5-option vignettes with full wrong-answer teaching.
• Study guide
  Tables, decision trees, primary sources.
• AI tutor
  Chapter-grounded, answers the question you're stuck on.

What this chapter covers

• Section 7.1: Autoimmune atrophic gastritis and pernicious anemia

  Autoimmune atrophic gastritis is the prototype of chronic non-H. pylori gastritis, and the entire phenotype falls out of one sentence about anatomy: autoimmune destruction of parietal cells is corpus-predominant and antral-sparing, and every downstream manifestation tracks the location of the lesion.

• Section 7.2: H. pylori cancer precursor cascade and Menetrier disease

  Chronic gastritis from H. pylori does not become gastric cancer overnight.

• Section 7.3: Zollinger-Ellison syndrome

  Zollinger-Ellison syndrome is the gastrin-driven ulcer disease that masquerades as refractory peptic ulcer disease, and the boards present it as the diagnosis to suspect in any of five scenarios: multiple ulcers, ulcers in unusual locations distal to the duodenal bulb, ulcers refractory to standard therapy, ulcers combined with secretory diarrhea, or ulcers in a patient with a family history of MEN1.

• Section 7.4: Gastric adenocarcinoma

  Gastric adenocarcinoma sorts cleanly into two histologic types, and the Lauren classification is the framework to use.

• Section 7.5: MALT lymphoma and gastric DLBCL

  Gastric lymphoma accounts for less than 5 percent of gastric neoplasms, but it occupies a disproportionate share of the boards because the management of the two main types diverges sharply at the first decision point.

• Section 7.6: Gastric NETs (carcinoid)

  Gastric neuroendocrine tumors arise from enterochromaffin-like (ECL) cells in the body and fundus or from enterochromaffin cells, and the boards group them into three types because the type sorts cleanly along the gastrin axis and dictates the management.

• Section 7.7: GIST

  Gastrointestinal stromal tumor is the model targeted-therapy GI cancer, and the boards test it because the molecular biology, the endosonographic appearance, and the drug selection align in a tight teaching package.

Podcast episodes

1. 01

   Atrophic Correa ZES

   Covers the chronic gastritides and precursor lesions of the stomach for boards, unified by what each disease does to gastrin. Teaches autoimmune atrophic gastritis, the H. pylori Correa cascade toward intestinal-type cancer, Menetrier disease, and Zollinger-Ellison syndrome. Emphasizes the two high-yield differentials: high gastrin sorted by gastric pH, and giant gastric folds sorted by acid output and biopsy.

   Read the transcript →
2. 02

   Gastric Tumors MALT NET GIST

   Episode two of the Gastritis and Gastric Cancers chapter works through the four gastric tumor families where histology and molecular driver are the discriminator: adenocarcinoma by Lauren type, MALT versus large B-cell lymphoma, the three gastric neuroendocrine tumors, and GIST as the model targeted-therapy cancer. Each tumor's biology drives its staging and its drug. Board-relevant triggers, molecular markers, and treatment sequences throughout.

   Read the transcript →

Key topics

• ·Autoimmune atrophic gastritis
• ·B12 and iron deficiency
• ·Type 1 gastric neuroendocrine tumors
• ·H. pylori Correa cascade
• ·Intestinal metaplasia staging and surveillance
• ·Menetrier disease
• ·Zollinger-Ellison syndrome
• ·MEN1 and gastrinoma triangle
• ·Gastric adenocarcinoma and the Lauren classification
• ·Hereditary diffuse gastric cancer and CDH1
• ·Adenocarcinoma staging and molecular profiling
• ·MALT versus large B-cell gastric lymphoma
• ·Three types of gastric neuroendocrine tumor
• ·GIST molecular biology and risk stratification
• ·Targeted therapy sequences (FLOT, R-CHOP, TKIs)